Meet CGT Global’s Scientific Team: Vanessa Murillo – Supervisor, Client Scientific Associate Team

October 08, 2025 Written by: Joanna Wirkus, PhD At CGT Global, advancing scientific discoveries worldwide by delivering high-quality biospecimens starts with providing exceptional service to our clients. Today, we’re highlighting how this happens by speaking with Vanessa Murillo, a core member and leader of CGT Global’s Client Scientific Associate team. Vanessa is a Client Scientific…

For More Information

5 Green Flags the FDA Looks for in CGT CMC and How to Get Them

Roughly 50–75% of FDA rejections in cell and gene therapy aren’t about safety or efficacy — they’re due to CMC and manufacturing deficiencies.In short, most programs don’t fail because the science doesn’t work — they fail because the manufacturing story isn’t strong enough.(Sources: Jefferies analysis of FDA complete response letters, FiercePharma 2024; multiple CMC audit…

For More Information

Baby KJ Makes Headlines as the First Infant to Receive Personalized CRISPR Gene Editing Therapy

Baby KJ Makes Headlines as the First Infant to Receive Personalized CRISPR Gene Editing Therapy

Written by Joanna Wirkus, PhD May 15, 2025, NPR ’s Science Friday spotlighted Baby KJ, the first infant to receive a personalized CRISPR-based gene editing treatment. The segment explored the groundbreaking therapy, the condition it aims to treat, and the collaborative effort behind this historic milestone. Here’s a summary of the key points from the…

For More Information

Alzheimer’s & Neurodegenerative Disease: A Global Challenge

Alzheimer’s & Neurodegenerative Disease: A Global Challenge

Written by CGT Global Cell & Gene Therapy Is Shifting the Paradigm Recent CGT innovations are upending traditional models and opening new paths to treat or even reverse Alzheimer’s progression: 1. AAV-Based Gene Therapy (LX1001) 2. CRISPR-Engineered Microglia 3. Behavior-Reprogramming Gene Therapy (UC San Diego) 4. Stem Cells & MSC Therapies 5. iPSC TriCulture Models…

For More Information

Mesenchymal Stem Cell Derived Exosomes: Revolutionizing Future Medical Treatments

Mesenchymal Stem Cell Derived Exosomes: Revolutionizing Future Medical Treatments

Why are scientists excited about Mesenchymal Stem Cell Exosomes? Mesenchymal stem cell (MSC) exosomes are on the brink of revolutionizing future treatments for chronic diseases and injuries. These microscopic biological messengers represent a vital mechanism of cellular communication, potentially offering a biomolecular reset for human physiological processes. The Unique Capabilities of Mesenchymal Stem Cells Mesenchymal…

For More Information

CGT Global Welcomes Dr. Jerome Ritz to Its Board of Advisors, Enriching Knowledge of Cellular Therapies and Hematology

By:CGT GlobalviaBusiness Wire August 14, 2025 at 09:00 AM EDT CGT Global, a biotechnology leader accelerating access to life-changing cell and gene therapies, today announced the appointment of Jerome Ritz, MD, to its Board of Advisors. Dr. Ritz brings a distinguished career in hematology, oncology, cell manufacturing, and the advancement of cell and gene therapies.…

For More Information

CGT Global Appoints Dr. Andrew Branagan to Board of Advisors, Expanding Cell and Gene Therapy Expertise

CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today announced the appointment of Andrew Robert Branagan, MD, PhD, to its Board of Advisors. Dr. Branagan brings extensive expertise in hematologic malignancies, immunology, and the development of novel therapeutic strategies, including cellular therapies. This press release features…

For More Information

Fast-Track Your Therapy Pipeline with CGT Global’s Clinical Capabilities

Fast-Track Your Therapy Pipeline with CGT Global’s Clinical Capabilitie

By: Joanna Wirkus  Despite exponential progress in the field of biology, inherited and preventable diseases continue to burden billions of people worldwide. Bridging the gap between laboratory discoveries and transformative clinical therapies remains a significant challenge, , and an urgent opportunity. High-quality biospecimens are foundational to this effort, enabling the advancement of cell and gene…

For More Information